Sana Biotechnology expects to file IND for SC291 in autoimmune diseases in Q4 2023, with clinical data in 2024

Sana Biotechnology, Inc.

Sana expects to file investigational new drug application for SC291 in autoimmune diseases in Q4 2023.
Clinical data from SC291 in autoimmune diseases expected in 2024.
Announcement made at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.